XSHE
000078
Market cap577mUSD
Oct 09, Last price
1.46CNY
1D
-0.68%
1Q
-22.75%
Jan 2017
-76.83%
Name
Shenzhen Neptunus Bioengineering Co. Ltd
Chart & performance
P/E
—
P/S
0.14
EPS
—
Div yield, %
—
Shrs. gr., 5y
0.02%
Rev. gr., 5y
-8.27%
Revenues
26.67b
-12.04%
Net income
-563m
L-52.82%
CFO
104m
+164.02%
Dividend
Jul 16, 20190.02 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Shenzhen Neptunus Bioengineering Co., Ltd. is a pharmaceutical enterprise primarily active in China, focusing on the research, development, production, and sale of various medicinal products. Its offerings span therapeutic categories such as anti-cancer treatments, cardiovascular and cerebrovascular medications, and pharmaceuticals derived from marine sources. Founded in 1989, the company is headquartered in Shenzhen, China.
Key people
Zhanjun Liu
Vice Chairman of the Board · since 2019
President, Vice Chairman of the Board · since 2019
Ling Luo
Vice President · since 2019
Xiaoming Shi
Vice President · since 2019
Tingjiu Song
Vice President · since 2013
Shuancheng Yang
Vice President · since 2019
Lin Yu
Vice President · since 2015
Fan Zhang
Vice President · since 2019
Simin Zhang
Chairman of the Board · since 2001
Yang Gu
Independent Director
Luoli Li
Independent Director · since 2010
Independent Director
Headquarters & legal address
深圳市南山区科技中三路1号海王银河科技大厦24层
深圳市, GD 100000
CN
深圳市, GD 100000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2022‑00 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2018‑00 | 2017‑12 | 2016‑12 | |
| Income | |||||||||||||
Revenues | |||||||||||||
Cost of revenue | |||||||||||||
Unusual Expense (Income) | |||||||||||||
NOPBT | |||||||||||||
NOPBT Margin | |||||||||||||
Operating Taxes | |||||||||||||
Tax Rate | |||||||||||||
NOPAT | |||||||||||||
Net income | |||||||||||||
Dividends | |||||||||||||
Dividend yield | |||||||||||||
Proceeds from repurchase of equity | |||||||||||||
BB yield | |||||||||||||
| Debt | |||||||||||||
Debt current | |||||||||||||
Long-term debt | |||||||||||||
Deferred revenue | |||||||||||||
Other long-term liabilities | |||||||||||||
Net debt | |||||||||||||
| Cash flow | |||||||||||||
Cash from operating activities | |||||||||||||
CAPEX | |||||||||||||
Cash from investing activities | |||||||||||||
Cash from financing activities | |||||||||||||
FCF | |||||||||||||
| Balance | |||||||||||||
Cash | |||||||||||||
Long term investments | |||||||||||||
Excess cash | |||||||||||||
Stockholders' equity | |||||||||||||
Invested Capital | |||||||||||||
ROIC | |||||||||||||
ROCE | |||||||||||||
| EV | |||||||||||||
Common stock shares outstanding | |||||||||||||
Price | |||||||||||||
Market cap | |||||||||||||
EV | |||||||||||||
EBITDA | |||||||||||||
EV/EBITDA | |||||||||||||
Interest | |||||||||||||
Interest/NOPBT | |||||||||||||